Your fact-checks will appear here
Ivermectin is being studied as a potential cancer therapy, with ongoing clinical trials and preclinical evidence showing promise, but clinical proof of efficacy and comprehensive toxicity profiles in cancer patients remain unreported.
Preclinical literature documents repeated instances where potentiates or reverses resistance to a range of and in cell lines and animal models, acting through mechanisms such as P‑glycoprotein (P‑gp/M...
No published case studies in the supplied reporting document a clear, directly attributed adverse event from coadministration of ivermectin specifically with chemotherapy supportive drugs; small clini...
Preclinical mouse studies of ivermectin report effective antitumor activity across a wide dose range—commonly 0.5–10 mg/kg and in some reviews up to 40 mg/kg—with many experiments using ~3–10 mg/kg to...